Exploring gene knockout strategies to identify potential drug targets using genome-scale metabolic models

Abhijit Paul1, Rajat Anand1, Sonali Porey Karmakar1

  • 1Complex Analysis Group, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd milestone, Faridabad-Gurgaon Expressway, Faridabad, 121001, India.

Scientific Reports
|January 9, 2021
PubMed

Insights

Computational models offer a faster, cheaper way to find cancer drug targets. This study used genome-scale metabolic models (GSMMs) to predict gene targets, validating findings with drugs like mitotane.

Area of Science:

  • Computational biology
  • Cancer research
  • Systems biology

Background:

  • Traditional cancer drug discovery relies on costly and time-consuming gene knockout studies or phenotypic screening.
  • Genome-scale metabolic models (GSMMs) present a promising computational alternative for identifying potential drug targets.

Purpose of the Study:

  • To evaluate the effectiveness of gene knockout strategies using GSMMs for identifying novel cancer drug targets.
  • To compare computational predictions with experimental data and existing screening results.

Main Methods:

  • Performed single-gene knockout simulations on GSMMs of NCI-60 cancer cell lines from nine tissue types.
  • Identified and ranked metabolic genes based on their impact on cancer cell growth reduction.
  • Analyzed growth reduction mechanisms and compared gene ranking with shRNA screening data.

Main Results:

  • Single-gene knockouts showed limited correlation with shRNA data but were significant for predicting drug activity against proliferation.
  • Multiple gene knockout analyses yielded improved correlation results.
  • Experimental validation confirmed that mitotane and myxothiazol inhibit the growth of at least four NCI-60 cell lines.

Conclusions:

  • GSMM-based gene knockout strategies are valuable for predicting cancer drug targets, especially when considering multiple gene interactions.
  • Computational approaches can guide experimental validation, accelerating the discovery of effective anti-cancer agents.